Bioventus Inc. recently delivered a presentation highlighting its market position and growth strategy at the Piper Sandler Healthcare Conference. The company reported $564 million in last twelve months $(LTM)$ global proforma revenue and identified a $6.4 billion market opportunity across pain treatments, surgical solutions, and restorative therapies. Bioventus emphasized its diversified portfolio, which includes hyaluronic acid, platelet rich plasma, ultrasonics, bone graft substitutes, and fracture care. The presentation outlined above-market revenue growth for eight consecutive quarters, a consistent mid-70s gross margin, and ongoing EBITDA margin expansion. The company also discussed its focus on accelerating cash flow, enhancing liquidity, and reducing net leverage below 2.5x by the end of 2025. You can access the full presentation through the link below.